Available datapackage for study 'A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)'

Vivli 2026 Dataset Open access

Read full text
Authors: Boehringer Ingelheim
DOI: 10.25934/pr00008832.2
Cited by: 0

Abstract

The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.

Publication details

Journal / source
Vivli
Publication date
8 January 2026
Language
EN
Document type
Dataset